Published in Infect Immun on January 01, 1988
Toxic shock syndrome toxin 1 binds to major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A (1989) 2.53
Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol (2005) 1.52
Toxic shock syndrome. Clin Microbiol Rev (1988) 1.37
Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect Immun (1993) 1.33
Correlation of temperature and toxicity in murine studies of staphylococcal enterotoxins and toxic shock syndrome toxin 1. Infect Immun (1999) 1.33
Diverse enterotoxin gene profiles among clonal complexes of Staphylococcus aureus isolates from the Bronx, New York. Appl Environ Microbiol (2009) 1.32
Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody. Infect Immun (1990) 1.31
Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One (2010) 1.03
A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity. Infect Immun (1995) 0.99
One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases. Eur J Clin Microbiol Infect Dis (2008) 0.98
Production of a toxic shock syndrome toxin variant by Staphylococcus aureus strains associated with sheep, goats, and cows. J Clin Microbiol (1989) 0.97
Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model. Infect Immun (1995) 0.96
Protection of rabbits in an infection model of toxic shock syndrome (TSS) by a TSS toxin-1-specific monoclonal antibody. Infect Immun (1988) 0.96
Persistence survey of toxic shock syndrome toxin-1 producing Staphylococcus aureus and serum antibodies to this superantigen in five groups of menstruating women. BMC Infect Dis (2010) 0.93
Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus. Virulence (2016) 0.86
Delineation by use of specific monoclonal antibodies of the T-cell receptor and major histocompatibility complex interaction sites on the superantigen toxic shock syndrome toxin 1. Infect Immun (1996) 0.83
A toxic shock syndrome toxin 1 mutant that defines a functional site critical for T-cell activation. Infect Immun (1995) 0.79
Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1. Toxins (Basel) (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (1985) 19.41
Interleukin-1. Rev Infect Dis (1984) 11.24
Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet (1978) 10.25
Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis (1981) 8.40
A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet (1981) 7.69
Potentiation of the T-lymphocyte response to mitogens. I. The responding cell. J Exp Med (1972) 6.52
Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med (1972) 6.47
Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med (1980) 4.68
Nonmenstrual toxic shock syndrome: a review of 130 cases. Ann Intern Med (1982) 3.12
Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet (1986) 2.69
Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C. Infect Immun (1982) 2.43
Induction of human interleukin-1 by toxic-shock-syndrome toxin-1. J Infect Dis (1985) 2.37
Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome. J Clin Invest (1984) 2.33
Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins. JAMA (1985) 2.16
A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect Immun (1987) 2.13
Production of staphylococcal enterotoxin F and pyrogenic exotoxin C by Staphylococcus aureus isolates from toxic shock syndrome-associated sources. Infect Immun (1983) 2.08
Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome. J Infect Dis (1983) 2.08
Toxicity of staphylococcal toxic shock syndrome toxin 1 in rabbits. Infect Immun (1984) 1.60
Characterization of Staphylococcus aureus isolates from patients with toxic shock syndrome, using polyethylene infection chambers in rabbits. Infect Immun (1983) 1.56
Induction of interleukin-1 by strains of Staphylococcus aureus from patients with nonmenstrual toxic shock syndrome. J Infect Dis (1986) 1.52
An enterotoxin-like protein in Staphylococcus aureus strains from patients with toxic shock syndrome. Ann Intern Med (1982) 1.48
Spleen cell analysis and optimal immunization for high-frequency production of specific hybridomas. Methods Enzymol (1983) 1.44
Expression of the cloned toxic shock syndrome toxin 1 gene (tst) in vivo with a rabbit uterine model. Infect Immun (1985) 1.43
Involvement of staphylococcal enterotoxins in nonmenstrual toxic shock syndrome. J Clin Microbiol (1986) 1.42
Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J Infect Dis (1984) 1.28
Analysis of the mitogenic effects of toxic shock toxin on human peripheral blood mononuclear cells in vitro. Clin Immunol Immunopathol (1984) 1.27
A rabbit model of toxic shock syndrome: clinicopathological features. J Infect (1984) 1.19
Visceral leishmaniasis in congenic mice of susceptible and resistant phenotypes: immunosuppression by adherent spleen cells. Infect Immun (1985) 1.15
Study of the biological activities of toxic shock syndrome toxin-1. I. Proliferative response and interleukin 2 production by T cells stimulated with the toxin. Microbiol Immunol (1986) 1.10
Affinity purification of staphylococcal toxic shock syndrome toxin 1 and its pathologic effects in rabbits. Infect Immun (1986) 1.05
Serum antibodies to enterotoxins produced by Staphylococcus aureus with special reference to enterotoxin F and toxic shock syndrome. J Clin Microbiol (1983) 0.96
Binding of toxic-shock-syndrome toxin-1 to human peripheral blood mononuclear cells. J Infect Dis (1987) 0.91
Epidemiology of toxic-shock syndrome, United States, 1960-1984. MMWR CDC Surveill Summ (1984) 0.78
The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med (1994) 16.32
Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis (1982) 8.05
Helicobacter pylori virulence and genetic geography. Science (1999) 7.64
Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA (1997) 4.49
Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia. J Clin Invest (1994) 3.40
Inhibition of in vitro protein synthesis by Shigella dysenteriae 1 toxin. Biochem Biophys Res Commun (1976) 3.30
Biological properties of Shigella flexneri 2A toxin and its serological relationship to Shigella dysenteriae 1 toxin. Infect Immun (1977) 2.94
The Department of Health's "two week standard" for bowel cancer: is it working? Gut (2004) 2.88
Characterization of Shigella dysenteriae 1 (Shiga) toxin purified by anti-Shiga toxin affinity chromatography. Infect Immun (1980) 2.82
Toxic shock syndrome toxin 1 binds to major histocompatibility complex class II molecules. Proc Natl Acad Sci U S A (1989) 2.53
Training in large bowel cancer surgery: observations from three prospective regional United Kingdom audits. BMJ (1999) 2.44
The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem (1992) 2.40
Induction of human interleukin-1 by toxic-shock-syndrome toxin-1. J Infect Dis (1985) 2.37
Indomethacin and perforated duodenal ulcer. Br Med J (1980) 2.21
A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect Immun (1987) 2.13
Production of exoenzyme S during Pseudomonas aeruginosa infections of burned mice. Infect Immun (1979) 1.86
Helicobacter pylori in the stomach--a paradox unmasked. N Engl J Med (1996) 1.85
Bascom's operation in the day-surgical management of symptomatic pilonidal sinus. Br J Surg (2000) 1.85
Streptococcus bovis endocarditis and its association with chronic liver disease: an underestimated risk factor. Clin Infect Dis (2004) 1.80
Changes over time in socioeconomic inequalities in breast and rectal cancer survival in England and Wales during a 32-year period (1973-2004): the potential role of health care. Ann Oncol (2011) 1.72
Production of tumor necrosis factor by human monocytes in response to toxic-shock-syndrome toxin-1. J Infect Dis (1988) 1.72
Interaction of magnesium ion, oxygen tension, and temperature in the production of toxic-shock-syndrome toxin-1 by Staphylococcus aureus. J Infect Dis (1987) 1.66
H pylori and gastric cancer. Lancet (1994) 1.62
Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins. J Infect Dis (1991) 1.62
Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment. Clin Infect Dis (2001) 1.60
Gastrin and colorectal cancer: a prospective study. Gastroenterology (1998) 1.57
Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut (2007) 1.57
Expression of type 8 capsular polysaccharide and production of toxic shock syndrome toxin 1 are associated among vaginal isolates of Staphylococcus aureus. J Clin Microbiol (1990) 1.54
Helicobacter pylori and gastric adenocarcinoma. Clin Microbiol Infect (2009) 1.53
Hydrodynamic structure of bovine serum albumin determined by transient electric birefringence. Biophys J (1975) 1.52
Induction of interleukin-1 by strains of Staphylococcus aureus from patients with nonmenstrual toxic shock syndrome. J Infect Dis (1986) 1.52
Cleft closure for the treatment of pilonidal sinus disease. Colorectal Dis (2011) 1.52
Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group. J Infect Dis (1997) 1.50
Simple and reliable enzyme-linked immunosorbent assay with monoclonal antibodies for detection of Escherichia coli heat-stable enterotoxins. J Clin Microbiol (1984) 1.48
Failure of prophylactic and therapeutic use of a murine anti-tumor necrosis factor monoclonal antibody in Escherichia coli sepsis in the rabbit. Crit Care Med (1995) 1.46
Testing negative for Helicobacter pylori after methylene blue spraying of gastric mucosa. Gastrointest Endosc (1994) 1.45
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis (2010) 1.45
Prevalence and incidence of herpes simplex virus type 2 infection among male Zimbabwean factory workers. J Infect Dis (1999) 1.44
Competitive, enzyme-linked immunosorbent assay for toxic shock syndrome toxin 1. J Clin Microbiol (1985) 1.41
Effect of a recombinant endotoxin-neutralizing protein on endotoxin shock in rabbits. Crit Care Med (1994) 1.41
Theory and application of static field inhomogeneity effects in gradient-echo imaging. J Magn Reson Imaging (1997) 1.40
Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive Toxoplasma immunoglobulin M antibody titers. Am J Obstet Gynecol (2001) 1.33
Revised amino acid sequence for a heat-stable enterotoxin produced by an Escherichia coli strain (18D) that is pathogenic for humans. Infect Immun (1985) 1.32
Evidence of the effect of 'specialization' on the management, surgical outcome and survival from colorectal cancer in Wessex. Br J Surg (2003) 1.32
Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody. Infect Immun (1990) 1.31
Rhesus monkey (Macaca mulatta) model of Helicobacter pylori: noninvasive detection and derivation of specific-pathogen-free monkeys. Lab Anim Sci (1999) 1.31
Rapid screening assay for toxic shock syndrome toxin production by Staphylococcus aureus. J Clin Microbiol (1984) 1.31
Citrobacter freundii produces an 18-amino-acid heat-stable enterotoxin identical to the 18-amino-acid Escherichia coli heat-stable enterotoxin (ST Ia). Infect Immun (1989) 1.31
Cultivation and serological characterization of a human Theiler's-like cardiovirus associated with diarrheal disease. J Virol (2010) 1.30
In vitro production of an extracellular protease by Legionella pneumophila. Infect Immun (1981) 1.26
Biologic sex as a risk factor for Helicobacter pylori infection in healthy young adults. Am J Epidemiol (1995) 1.24
Patterns of health seeking behavior during episodes of childhood diarrhea: a study of Tzotzil-speaking Mayans in the highlands of Chiapas, Mexico. Soc Sci Med (1999) 1.21
Determination of the infectious dose of Helicobacter pylori during primary and secondary infection in rhesus monkeys (Macaca mulatta). Infect Immun (2001) 1.21
Flagellar serotypes of Salmonella typhi in Indonesia: relationships among motility, invasiveness, and clinical illness. J Infect Dis (1995) 1.21
Phosphatidylinositol-specific phospholipase C, a possible virulence factor of Staphylococcus aureus. J Clin Microbiol (1989) 1.17
Toxic shock syndrome toxin-1 induces inositol phospholipid turnover, protein kinase C translocation, and calcium mobilization in human T cells. J Immunol (1988) 1.17
Evaluation of Delorme's procedure as a treatment for full-thickness rectal prolapse. Br J Surg (2000) 1.16
Hepatitis C and steatosis: a reappraisal. J Viral Hepat (2006) 1.16
Association of Helicobacter pylori infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. Am J Med (1990) 1.13
Biological and immunological characteristics of 125I-4Tyr and -18Tyr Escherichia coli heat-stable enterotoxin species purified by high-performance liquid chromatography. Anal Biochem (1985) 1.12
Control of production of toxic-shock-syndrome toxin-1 (TSST-1) by magnesium ion. J Infect Dis (1985) 1.11
Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease. Am J Gastroenterol (2001) 1.10
Binding of E. coli heat-stable enterotoxin to rat intestinal brush borders and to basolateral membranes. Dig Dis Sci (1987) 1.07
Disease stage and psychosocial outcomes in colorectal cancer. Colorectal Dis (2008) 1.05
Shigellosis and Escherichia coli diarrhea: relative importance of invasive and toxigenic mechanisms. Am J Clin Nutr (1979) 1.05
Social deprivation and outcomes in colorectal cancer. Br J Surg (2006) 1.05
Comparison of circumferential margin involvement between restorative and nonrestorative resections for rectal cancer. Colorectal Dis (2005) 1.03
Blinded, two-laboratory comparative analysis of Escherichia coli heat-stable enterotoxin production by using monoclonal antibody enzyme-linked immunosorbent assay, radioimmunoassay, suckling mouse assay, and gene probes. J Clin Microbiol (1986) 1.02
Acute Helicobacter pylori infection is followed by an increase in diarrheal disease among Peruvian children. Pediatrics (2001) 1.01
Interobserver variability in application of the revised Sydney classification for gastritis. Hum Pathol (1999) 1.01
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients. Aliment Pharmacol Ther (2006) 1.01
Synthesis and proof of structure of the new amino acid in prothrombin. Biochem Biophys Res Commun (1975) 1.01
Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev (2001) 0.98
Gastric mucosal lesions produced by intravenous infusion of aspirin in cats. Gastroenterology (1976) 0.98
On the pathogenesis of toxic shock syndrome. Rev Infect Dis (1988) 0.97
Protection of rabbits in an infection model of toxic shock syndrome (TSS) by a TSS toxin-1-specific monoclonal antibody. Infect Immun (1988) 0.96
Hepatic inactivation of gastrins of various chain lengths in dogs. Gastroenterology (1978) 0.96
Endotoxemia in a series of 104 patients with chronic liver diseases: prevalence and significance. Digestion (1982) 0.96
Gastric adenocarcinoma and Helicobacter pylori infection. West J Med (1994) 0.95
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C. J Viral Hepat (2013) 0.95
Molecular epidemiologic techniques in analysis of epidemic and endemic Shigella dysenteriae type 1 strains. J Infect Dis (1991) 0.95
Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies. Clin Transplant (2001) 0.94
Characterization of human beta-interferon-binding sites on human cells. J Biol Chem (1985) 0.94
THE NEW ERGOT ALKALOID. Science (1936) 0.94
The association of Helicobacter pylori with gastric cancer and preneoplastic gastric lesions in Chiapas, Mexico. Cancer (1993) 0.94
ApoE polymorphisms and diarrheal outcomes in Brazilian shanty town children. Braz J Med Biol Res (2010) 0.93
Implantation metastasis from adenocarcinoma of sigmoid colon into fistula in ano. J R Soc Med (1992) 0.92
When heredity is infectious. Gastroenterology (2000) 0.92
Helicobacter pylori and risk for gastric adenocarcinoma. Semin Gastrointest Dis (2001) 0.92
Polymyositis after ciguatera toxin exposure. Arch Neurol (1991) 0.92
QuantiFERON-TB predicts tuberculin skin test boosting in U.S. foreign-born. Int J Tuberc Lung Dis (2005) 0.91
Antifreeze glycoproteins from the blood of an antarctic fish. The structure of the proline-containing glycopeptides. J Biol Chem (1978) 0.91
Physiological changes after Delorme's procedure for full-thickness rectal prolapse. Br J Surg (1995) 0.91
Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3 infected patients. J Viral Hepat (2008) 0.91
Synergistic effect of glucantime and a liposome-encapsulated muramyl dipeptide analog in therapy of experimental visceral leishmaniasis. Infect Immun (1985) 0.91